JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Bristol-Myers Squibb Co.

Cerrado

SectorSalud

46.18 0.46

Resumen

Variación precio

24h

Actual

Mínimo

45.69

Máximo

46.12

Métricas clave

By Trading Economics

Ingresos

1.3B

3.8B

Ventas

1.1B

12B

P/B

Media del Sector

18.414

34.393

BPA

1.46

Rentabilidad por dividendo

5.42

Margen de beneficio

30.769

Empleados

34,100

EBITDA

1.9B

4.5B

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+12.36% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

5.42%

2.54%

Próximas Ganancias

30 oct 2025

Fecha Próximo Dividendo

31 oct 2025

Próxima Fecha de Ex Dividendo

3 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-2B

93B

Apertura anterior

45.72

Cierre anterior

46.18

Noticias sobre sentimiento de mercado

By Acuity

35%

65%

113 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Bristol-Myers Squibb Co. Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

31 jul 2025, 11:14 UTC

Ganancias

Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q

2 jun 2025, 11:48 UTC

Principales Movimientos del Mercado

BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 Billion

4 ago 2025, 11:59 UTC

Ganancias

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

31 jul 2025, 11:54 UTC

Ganancias

Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 2Q Growth Portfolio Revenue Rose 18% to $6.6B >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb Cuts 2025 View To Adj EPS $6.35-Adj EPS $6.65 Vs Prior View $6.70-$7.00 >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 2Q Adjusted Gross Margin 72.6% >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 2Q Adj EPS $1.46 >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 2Q International Revenue Rose 10% to $3.75B >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb Raises 2025 View To Rev $46.5B-$47.5B From Prior View $45.8B-$46.8B >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Expected Continued Generic Impact Across Remainder of Legacy Portfolio, as Well as Impacts From U.S. Medicare Part D Redesign >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb: In Back Half of Year, Focused on Advancing Transformational Medicines and Delivering on Our Growth Portfolio and Important Pipeline Opportunities to Shape Our Growth Trajectory >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb: Raised 2025 Rev Guidance Reflecting Strength of Growth Portfolio, Better-Than-Expected Legacy Portfolio Sales in 2Q and Favorable Impact of About $200M Related to Foreign Exchange Rates >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb: Latest 2Q Includes Net Impact of Loss of 57c/Shr Due to Acquired IPRD Charge Associated With BioNtech Strategic Partnership >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Immuno-Oncology Portfolio, Breyanzi, Reblozyl and Camzyos, and Reflects Continued Strength of Cobenfy >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 2Q Legacy Portfolio Rev Fell 14% to $5.67B >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 2Q Gross Margin 72.5% >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 2Q Rev $12.27B >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Beats Earnings Expectations. It's Still Optimistic About New Schizophrenia Drug. -- Barrons.com

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb: Revised 2025 Adj EPS Guidance Inclusive of BioNTech Acquired IPRD Chg in 2Q >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 2Q U.S. Revenue Fell 3% to $8.52B >BMY

31 jul 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 2Q EPS 64c >BMY

12 jun 2025, 14:20 UTC

Adquisiciones, fusiones, absorciones

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

13 may 2025, 16:48 UTC

Adquisiciones, fusiones, absorciones

2seventy bio: Bristol Myers Squibb Completes Acquisition of 2seventy

12 may 2025, 22:14 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 may 2025, 18:45 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 may 2025, 17:14 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12 may 2025, 12:07 UTC

Charlas de Mercado

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

7 may 2025, 20:09 UTC

Ganancias
Adquisiciones, fusiones, absorciones

2seventy Bio 1Q Rev $22.9M >TSVT

7 may 2025, 20:08 UTC

Ganancias
Adquisiciones, fusiones, absorciones

2seventy Bio 1Q EPS 1c >TSVT

Comparación entre iguales

Cambio de precio

Bristol-Myers Squibb Co. Esperado

Precio Objetivo

By TipRanks

12.36% repunte

Estimación a 12 meses

Media 51.63 USD  12.36%

Máximo 65 USD

Mínimo 34 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bristol-Myers Squibb Co. Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

20 ratings

4

Comprar

15

Mantener

1

Vender

Puntuación técnica

By Trading Central

N/A / 50.57Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

113 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.